You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: 5,260,074


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,260,074
Title: Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Abstract:Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, impaired liver function, cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering the compositions to a mammal in need of such treatment.
Inventor(s): Sipos; Tibor (Lebanon, NJ)
Assignee: Digestive Care Inc. (Lebanon, NJ)
Application Number:07/901,734
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 5,260,074: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 5,260,074, though not directly provided in the sources, can be analyzed through the lens of general patent law and the principles governing patent claims and scope. Here, we will delve into the key aspects of patent claims, the legal framework, and how these elements apply to any patent, including one like 5,260,074.

Understanding Patent Claims

Patent claims are the heart of a patent application, defining the scope of the invention for which protection is sought. These claims must be clear, concise, and fully supported by the description in the patent specification[2].

Types of Patent Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.
  • Method Claims: Describe a process or method for achieving a particular result.
  • Apparatus Claims: Describe a physical device or system.
  • Composition of Matter Claims: Describe a new chemical compound or material[3].

Legal Framework for Patent Claims

In the United States, patent eligibility is governed by 35 U.S.C. § 101, which requires that an invention fit into one of the categories of a process, machine, manufacture, or composition of matter. However, even if an invention falls into one of these categories, it may still be ineligible due to judicial exceptions that exclude laws of nature, natural phenomena, and abstract ideas[2].

The Problem with Result-Oriented Claims

Claims that merely describe a desired result without detailing the method or process for achieving that result are often deemed ineligible under § 101. The courts require some form of innovation that transforms the abstract idea into a concrete invention. For example, in Interval Licensing LLC v. AOL Inc. and American Axle & Manufacturing v. Neapco Holdings LLC, the courts invalidated claims that were too result-oriented and lacked specific technological methods for achieving the desired outcomes[2].

Patent Scope and Measurements

The scope of a patent is crucial in determining its validity and enforceability. The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents and applications, helping in the analysis of patent scope. This dataset includes claim-level statistics and document-level statistics, which can be used to understand the breadth and depth of patent claims[3].

Patent Landscape and Global Considerations

The global patent landscape is increasingly interconnected. Tools like the Global Dossier and the Common Citation Document (CCD) facilitate the search and analysis of patent applications across different jurisdictions. These tools help in identifying prior art and understanding the global patent family of an application, which is essential for assessing the novelty and non-obviousness of an invention[4].

Case Law and Precedents

Several Federal Circuit cases have set precedents for what constitutes a valid patent claim. For instance, Contour IP Holding LLC v. GoPro, Inc. reaffirmed that claims must offer a specific, inventive method for achieving the claimed result. These cases emphasize the importance of detailing the method or process in patent claims to avoid being deemed abstract and ineligible for patent protection[2].

Drafting Valid Patent Claims

For inventors and patent applicants, it is crucial to draft claims that are specific, clear, and supported by the patent specification. Claims should describe the concrete steps or processes required to achieve the claimed result and include an inventive concept that transforms the claim into something patent-eligible. Generic or routine steps without an inventive concept are unlikely to pass the test of patent eligibility[2].

Examples and Illustrations

To illustrate, consider a patent like US 8,268,305 B1, which details a method and composition for reducing serum levels of triglycerides using a fungal lipase. This patent provides specific details on the types of lipase, the reaction times, and the environments in which the process is carried out, making it a concrete and inventive method rather than a mere result-oriented claim[1].

Key Takeaways

  • Specificity in Claims: Patent claims must be specific and detail the method or process for achieving the claimed result.
  • Inventive Concept: Claims must include an inventive concept that transforms the abstract idea into a concrete invention.
  • Global Considerations: Understanding the global patent landscape is crucial for assessing the novelty and non-obviousness of an invention.
  • Case Law: Federal Circuit cases provide clear guidelines on what constitutes valid patent claims.
  • Drafting Claims: Claims should be clear, concise, and fully supported by the patent specification.

Frequently Asked Questions (FAQs)

Q1: What is the significance of 35 U.S.C. § 101 in patent law? A1: 35 U.S.C. § 101 governs patent eligibility, requiring inventions to fit into categories of process, machine, manufacture, or composition of matter, and excluding laws of nature, natural phenomena, and abstract ideas.

Q2: Why are result-oriented claims often ineligible for patent protection? A2: Result-oriented claims are often deemed ineligible because they lack specific methods or processes for achieving the desired result, failing to meet the inventive concept requirement.

Q3: How does the USPTO's Patent Claims Research Dataset help in patent analysis? A3: The dataset provides detailed information on claims from U.S. patents and applications, including claim-level and document-level statistics, which help in analyzing patent scope and trends.

Q4: What is the importance of the Global Dossier in patent searches? A4: The Global Dossier facilitates the search and analysis of patent applications across different jurisdictions, providing access to file histories, classification, and citation data.

Q5: What are some key precedents for valid patent claims? A5: Cases like Interval Licensing LLC v. AOL Inc. and American Axle & Manufacturing v. Neapco Holdings LLC set precedents that claims must include specific methods or processes and an inventive concept to be patent-eligible.

Citations

  1. United States Patent and Trademark Office, "US 8,268,305 B1 - METHOD AND COMPOSITIONS TO REDUCE SERUM LEVELS OF TRIGLYCERIDES IN HUMAN BEINGS USING A FUNGAL LIPASE," September 18, 2012.
  2. Vklaw, "Patently Unclear: Why Result-Oriented Claims Don't Make the Cut Under 35 U.S.C. § 101," September 27, 2024.
  3. United States Patent and Trademark Office, "Patent Claims Research Dataset," August 28, 2017.
  4. United States Patent and Trademark Office, "Search for patents," October 18, 2018.

More… ↓

⤷  Subscribe

Details for Patent 5,260,074

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Discure Medical, Llc CHYMODIACTIN chymopapain For Injection 018663 November 10, 1982 ⤷  Subscribe 2040-03-30
Discure Medical, Llc CHYMODIACTIN chymopapain For Injection 018663 August 21, 1984 ⤷  Subscribe 2040-03-30
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 December 09, 1996 ⤷  Subscribe 2040-03-30
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 April 30, 2009 ⤷  Subscribe 2040-03-30
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 June 10, 2011 ⤷  Subscribe 2040-03-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.